Differential inhibition of PDKs by phenylbutyrate and enhancement of pyruvate dehydrogenase complex activity by combination with dichloroacetate by unknown
ORIGINAL ARTICLE
Differential inhibition of PDKs by phenylbutyrate
and enhancement of pyruvate dehydrogenase complex
activity by combination with dichloroacetate
Rosa Ferriero & Clara Iannuzzi & Giuseppe Manco &
Nicola Brunetti-Pierri
Received: 6 August 2014 /Revised: 13 December 2014 /Accepted: 19 December 2014 /Published online: 20 January 2015
# The Author(s) 2015. This article is published with open access at Springerlink.com
Abstract Pyruvate dehydrogenase complex (PDHC) is a
key enzyme in metabolism linking glycolysis to tricar-
boxylic acid cycle and its activity is tightly regulated by
phosphorylation catalyzed by four pyruvate dehydroge-
nase kinase (PDK) isoforms. PDKs are pharmacological
targets for several human diseases including cancer, di-
abetes, obesity, heart failure, and inherited PDHC defi-
ciency. We investigated the inhibitory activity of
phenylbutyrate toward PDKs and found that PDK iso-
forms 1-to-3 are inhibited whereas PDK4 is unaffected.
Moreover, docking studies revealed putative binding
sites of phenylbutyrate on PDK2 and 3 that are located
on different sites compared to dichloroacetate (DCA), a
previously known PDK inhibitor. Based on these find-
ings, we showed both in cells and in mice that
phenylbutyrate combined to DCA results in greater in-
crease of PDHC activity compared to each drug alone.
These results suggest that therapeutic efficacy can be
enhanced by combination of drugs increasing PDHC
enzyme activity.
Introduction
Pyruvate dehydrogenase complex (PDHC; E.C. 1.2.4.1) is a
key enzyme in metabolism that catalyzes oxidative decarbox-
ylation of pyruvate to produce acetyl-CoA thus linking
glycolysis to tricarboxylic acid cycle. PDHC is a large
enzyme complex organized around a structural core
formed by dihydrolipoamide acetyltranferase (E2 pro-
tein) and E3-binding protein (E3BP). Multiple copies
of α2β2 heterotetramer pyruvate decarboxylase (E1),
the dihydrolipoamide dehydrogenase (E3), and one to
two copies each of pyruvate dehydrogenase kinases
(PDK; E.C. 2.7.11.2) and pyruvate dehydrogenase phos-
phatases (PDP; E.C. 3.1.3.43) are non-covalently bound
to the E2/E3BP core. PDKs bind via interactions to the
inner lipoyl domain (L2) of the E2 subunit (Liu et al 1995;
Hiromasa et al 2004; Roche and Hiromasa 2007). PDHC ac-
tivity is tightly regulated by reversible phosphorylation and
dephosphorylation. Phosphorylation of E1α at three specific
serine sites (Ser203-α, Ser264-α, Ser271-α) by four mito-
chondrial PDK isoforms (PDK1, PDK2, PDK3, and PDK4)
inactivates the complex whereas dephosphorylation by PDP1
and PDP2 restores enzyme activity. Phosphorylation of only
one site renders the enzyme inactive but the physiological
significance of the three phosphorylation sites, as well as the
need of multiple PDK isoenzymes, has yet to be elucidated.
PDHC activity is regulated by transcriptional levels of PDKs
and PDPs under different nutritional or disease states. PDK4
and to a lesser extent PDK2 are upregulated in tissues under
starvation and diabetes whereas PDPs are downregulated. As
a result, under these conditions PDHC activity is reduced for
glucose conservation (Harris et al 2001).
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PDKs are pharmacological targets for several human dis-
eases including cancer, diabetes, obesity, heart failure, and
inherited PDHC deficiency. PDK isoforms are expressed in
most tissues and based on similarity of their catalytic domains
(Bowker-Kinley and Popov 1999), are grouped within the
ATPase/kinase superfamily (composed of bacterial histidine
protein kinase, DNA gyrases, and molecular chaperone
HSP90). Members of this superfamily share four conserved
motifs forming a unique ATP-binding fold (Dutta and Inouye
2000) that includes the ATP lid, whose conformational change
is coupled to both ATP hydrolysis and protein-protein interac-
tions (Machius et al 2001). The four PDK isoforms belong to
the family of mitochondrial protein kinases that includes the
branched-chain α-ketoacid dehydrogenase kinase (BDK; EC
2.7.11.4) in which motifs that normally occur in eukaryotic
Ser/Thr/Tyr kinases are absent (Manning et al 2002).
Structural studies of PDKs and BDK have revealed that
these kinases consist of two distinct domains (Machius
et al 2001): the N-terminal regulatory domain formed by
eight α-helices with a four-helix bundle-like structure
forming the core and the C-terminal catalytic domain contain-
ing the phosphotransfer catalytic site that is conserved in the
ATPase/kinase superfamily (Dutta and Inouye 2000).
The primary structures of the four PDKs are conserved
with 66-74 % identity (Popov et al 1994). PDKs differ in their
catalytic activity, responsiveness to modulators such as
NADH and acetyl-CoA, and tissue-specific expression
(Bowker-Kinley and Popov 1999). PDK1 is highly expressed
in heart, PDK2 is ubiquitously expressed, PDK3 has a rela-
tively limited tissue distribution (mostly in testis and to a less-
er extent in brain, lung, and kidney), and PDK4 is expressed in
heart and skeletal muscle (Gudi et al 1995; Bowker-Kinley
et al 1998). PDK2 is expressed at higher levels compared to
other isoenzymes, suggesting that it may be the major
isoform responsible for regulation of PDHC enzyme ac-
tivity (Gudi et al 1995). Each PDK isoform exhibits dif-
ferent specificity for the three E1α serine sites; sites 1 and 2
are phosphorylated by all four isoforms whereas site 3 is only
modified by PDK1 (Kolobova et al 2001; Korotchkina and
Patel 2001a, b). PDK3 binds to L2 of the E2 protein most
tightly among the four PDK isoforms.
We have previously shown that phenylbutyrate inhibits
PDHC inactivation by competing for binding of E1α to
PDK2 through a competitive inhibition with an experimental-
ly measured Ki of 0.33±0.08 mM (Ferriero et al 2013).
Through a docking simulation, we also identified two putative
binding sites of phenylbutyrate on PDK2: one site was found
near the ATP lid and the other at the base of the four helix
cluster corresponding to the binding site of Pfz3, an allosteric
inhibitor of PDK2 (Knoechel et al 2006; Ferriero et al 2013).
The goal of this study was to investigate phenylbutyrate
inhibiting activity toward the other PDK isoenzymes
(PDK1, 3, and 4) and the relative drug binding sites. The
identification of phenylbutyrate binding sites on PDKs led
us to hypothesize that a combined therapy might be more
effective than mono-therapy at increasing enzyme activity
for therapeutic applications.
Materials and methods
Pyruvate dehydrogenase kinase activity assay
Recombinant human PDK1, PDK3, and PDK4 (Sigma-
Aldrich), and E1α [(30–390) plus His tag; molecular weight:
47 KDa] (Sigma-Aldrich) were used for the assays. PDK ac-
tivity was measured in duplicate as the initial rate of incorpo-
ration of [32P]-phosphate into E1α with 0.2 mM [γ-32P]ATP
(150–500 cpm/pmol) at 30 °C (Rahmatullah and Roche 1985;
Ravindran et al 1996; Baker et al 2000). The activitymeasured
at different time points (30-60-90-120 sec) and protein con-
centrations (from 50 ng to 800 ng) was established as linear
relative to time and protein concentrations. The assay used
0.02μg of PDKs andmeasured incorporation after 45 seconds
of reaction time. The assay was conducted in a total volume of
50 μl with a buffer Awith a final pH of 7.4 and the following
composition: 113 mM HEPES-Tris pH 7.4, 60 mM KCl,
30 mM K-HEPES, 2 mM MgCl2, 0.2 mM EDTA. The assay
mixture also contained 2mMdithiothreitol. Concentrated pro-
tein components (8-6-3-2-1-0.5 μg of E1α) were pre-
incubated for 60 minutes at 4 °C in the buffer in which they
were prepared and then were added to reaction mixtures for
2 minutes at 30 °C prior to initiation of PDK activity.
Phenylbutyrate was added at the concentration of 0.25 mM,
0.5 mM, or 1 mM and then the proteins were incubated in
buffer A at 22 °C for 60 seconds, and 0.2 mM of
[γ-32P]ATP was added. The reaction was terminated by
adding 2 mM of ATP, and labeled E1α was separated from
unbound ATP by loading 35 μl of mixture onto G-25
Sephadex gel filtration columns (10×0.45 mm). The reaction
mixtures eluted at the void volume (around 200 μl) were ap-
plied to dry paper (Whatman 3MM, 22 mm) previously
soaked in 10 % (w/v) trichloroacetic acid. The assay was
completed by reading incorporated cpm in vials containing
liquid scintillation cocktail in a Beckman LS6500 multi-
purpose scintillation counter. Data were analyzed with
GraFit Data Analysis Software version 5.0.
Docking of phenylbutyrate on PDK2 and PDK3
Protein-ligand docking simulations were performed
using AutoDock Vina tool (Trott and Olson 2010).
The initial PDK models were generated by building hy-
drogen atoms for the crystal structure of human PDK3
radicicol-bound (PDB chain ID 2Q8I) and human PDK2
ADP-bound (PDB chain ID 2BU8) and by adding
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Gasteiger charges. An initial conformation of the li-
gands [phenylbutyrate and dichloroacetate (DCA)] was
generated by Cartesian optimization of the ligand model
in GROMOS87 force field (PRODRG at http://davapc1.
bioch.dundee.ac.uk/prodrg/submit2.html). All side chains
and the backbone of the protein were kept rigid as in the
crystal structure. Docking was performed first by placing the
ligand in a random position by centering the grid on the
macromolecule and setting the grid with a 1-Å spacing on
the entire protein; after the identification of the best binding
sites, further analysis was performed by starting with the
ligand in the binding pockets and setting the grid with a 0.
375-Å spacing. The affinity expressed in kcal/mol was calcu-
lated as the difference in free energy of binding (ΔG) between
the protein and the complex. Control of docking procedure
was obtained by docking DCA on the PDK2 structure (PDB
chain ID 2BU8) after ligand and potassium ion removal and
by docking phenylbutyrate on the Val62Leu mutant PDK2
model obtained using the tools and procedures available
under the deepView/Swiss-Pdb Viewer program (v 4.1.
0). Results were visualized using PyMol (The PyMOL
Molecular Graphics System, Version 1.5.0.4 Schrodinger,
LLC) wherein conformations for each ligand were found to be
within the cavity of protein indicating that the docking run
was free from errors.
Mouse studies
Mouse studies were approved by the Italian Ministry of
Health. Phenylbutyrate (Ammonaps, Swedish Orphan
Internaltional Lab), phenylacetate (Sigma), DCA (Sigma), or
saline were given orally to C57BL/6 mice (Charles River
Laboratories) by gavage into doses divided in three daily ad-
ministrations for three consecutive days (at least n=5 mice per
group). After three days of treatment, animals were sacrificed
and brain, liver, and muscle were harvested after cardiac per-
fusion with phosphate buffered saline (PBS). Crude mito-
chondria were purified from tissues as previously reported
and assayed for PDHC activity as described below (Ferriero
et al 2013).
PDHC enzyme assay and western blots
Human control fibroblasts from normal subjects (BA1020 and
NA489) and fibroblasts from a male patient with PDHC defi-
ciency carrying the p.N135S mutation in the PDHA1 gene
(Ferriero et al 2013) were cultured in Dulbecco’s modified
Eagle’s medium and 1 % fetal bovine serum.
For PDHC enzyme assays, cultured skin fibroblasts were
harvested with trypsin solution and centrifuged. After centri-
fugation, the pellets were washed twice with PBS. The cell
pellet was resuspended in 2 ml buffer A (MOPS, 20mMKOH
pH 7.4, 250 mM sucrose) and 0.2 mg of digitonin for every ml
of buffer A. The solution was mixed and kept on ice for 5 mi-
nutes and centrifuged at 5000×g for 3 minutes. The superna-
tant was mixed with 3 ml buffer B (MOPS, KOH 20 mM
pH 7.4, sucrose 250 mM, EDTA Na4 1 mM), kept on ice for
5 minutes, then centrifuged at 10,000×g for 3 minutes. The
supernatants were discarded, and pellets were resuspended in
0.5 ml of 20 mM K-phosphate buffer pH 7.4, and then frozen
in liquid nitrogen and thawed at 37 °C three times. PDHC
enzyme activity was measured in mitochondrial fractions as
described previously (DeVivo et al 1979). Briefly, the assay
mixture contained 30 mM HEPES-KOH, 10 mM β-
mercaptoethanol, 1 mM CoASH, 0.1 mM NAD, 0.3 mM thi-
amine pyrophosphate, 0.02 % Triton, 10 mM MgCl2, and
1 mM CaCl2. The enzyme reaction was initiated with
20 mM of 14C-pyruvate sodium (Perkin Elmer) and incubated
for 10 minutes at 37 °C. Reaction was terminated with 250 μl
of 1 N HCl on ice and left at 37 °C for 60 minutes. The 14CO2
released from the reaction was captured onto filter paper and
transferred in scintillation liquid overnight; the cpm were
counted by a β-counter (Beckman LS6500). PDHC enzyme
activity was expressed as nmol/min/mg protein. Mitochondria
fractions quantified for protein concentrations by the Bradford
method (Bradford 1976) were resolved by SDS-PAGE and
transferred onto a PVDF membrane. Western blotting analy-
ses with 10 μg of mitochondrial fraction were performed with
PhosphoDetect anti-PDH-E1α (p-Ser264-α; Calbiochem
AP1062), anti-PDH-E1α (Abcam ab110416), and HRP-
conjugated secondary antibodies (GE Healthcare) diluted in
5 % milk in tris-buffered saline plus Tween 20 (TBST) and in
1 % BSA in TBST. Bands were visualized with a chemilumi-
nescence detection system (Pierce) and quantified with
Quantity One 1-D Analysis Software version 4.6.7 (Bio-Rad
Laboratories).
Statistical analyses
Statistical significance was computed using the Student’s 2
tail test. A p-value<0.05 was considered statistically
significant.
Results
Phenylbutyrate is rapidly metabolized to phenylacetate in vivo
(Mokhtarani et al 2012). In contrast to phenylbutyrate,
phenylacetate does not affect PDHC activity in fibroblasts
(Fig. 1) and does not increase enzyme activity in brain, mus-
cle, and liver of wild-type mice (Fig. 2).
We have previously reported that phenylbutyrate inhibition
of PDK2 toward E1α substrate is reversible and competitive
(Ferriero et al 2013). Here, we sought to investigate whether
phenylbutyrate has inhibitory activity toward the other PDK
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isoenzymes (PDK1, PDK3, and PDK4) and the type of inhi-
bition under the same conditions. These enzyme assays were
performed on E1α substrate without E2, E1β, and other com-
ponents of the complex. In Table 1, kinetic values of the four
PDK isoenzymes obtained using recombinant PDK1, PDK2,
PDK3, and PDK4 proteins are reported. Consistent with pre-
vious studies (Korotchkina and Patel 2001a, b), PDK2 is the
isoenzyme with a much higher Vmax compared to the other
PDKs, whereas the four PDKs show little differences in
their apparent Km, reflecting affinity for the E1α sub-
st ra te . PDK1 and PDK3 were both inhibi ted by
phenylbutyrate (Fig. 3a and b) whereas no inhibitory effect
on PDK4 isoenzyme was observed (Fig. 3c). In primary
Lineweaver-Burk plots, in the absence or in the presence of
increasing concentrations of phenylbutyrate, a set of
parallel and straight lines is obtained as a result of a con-
comitant but opposite effect of phenylbutyrate on Km and
Vmax (Fig. 3a and b), thus showing uncompetitive inhibition
on phosphorylation (Dixon and Webb 1979; Whiteley 2000).
By plotting the values of intercepts on the y axis of the
Lineweaver-Burk plot against inhibitor concentrations, the
effect of phenylbutyrate on PDK1 and 3 can be compared
(Fig. 3d). Compared to PDK1, the significantly lower
Ki of phenylbutyrate for PDK3 (Table 1) indicates that
phenylbutyrate is a stronger inhibitor of PDK3.
Docking studies
For PDK2, we previously identified by docking simulation
two binding sites for phenylbutyrate: one near the ATP lid
with a predicted binding affinity of −4.0 kcal/mol and the
other at the base of the four helix cluster (Pfz3 binding site)
(Knoechel et al 2006) with a predicted binding affinity of
−5.6 kcal/mol (Ferriero et al 2013). The PDK2 structure used
for this simulation was an ATP-free structure (PDB ID 2BU7)
and because of the high affinity of PDK2 for ATP, we here
performed a docking simulation of phenylbutyrate toward the
ADP-bound structure of PDK2 (PDB ID 2BU8) to simulate
conditions occurring both in vitro and in vivo. When the ATP
binding site is occupied, only the Pfz3 binding site was iden-
tified with an even higher binding affinity (−6.9 kcal/mol) in
the PDK2 structure compared to the PDK2 ATP-free form
(−5.6 kcal/mol) (Ferriero et al 2013). This result suggests that
this region in PDK2 is likely to be the most relevant binding
site involved in phenylbutyrate inhibition. This binding
pocket for phenylbutyrate is located at one of the highly
lipophilic four-helix bundle of PDK2 (Fig. 4a). Val67
located in the middle of this pocket is likely to play an
important role in stabilizing binding to phenylbutyrate
(Fig. 4b and Supplementary Fig. 1a). Interestingly, this residue
is unique to human PDK2 whereas at that amino acid position
the other three isoforms have a leucine that has a larger side
chain which could restrict the access of phenylbutyrate to the
binding pocket. Docking of phenylbutyrate on a PDK2 model
in which Val67 was replaced in silico with leucine indeed
resulted in lack of drug binding at this site.
Because of the stronger inhibitory effect and its importance
as an anti-cancer target (Lu et al 2008; Kluza et al 2012), we
searched for phenylbutyrate binding site on PDK3. Through a
Fig. 1 PDHC activity in cells treated with phenylacetate or
phenylbutyrate. PDHC activity in wild-type human fibroblasts incubated
with 1 mM or 10 mM of phenylbutyrate (red) or phenylacetate (blue) for
24 hours, or untreated (black). Averages±SD are shown; * p<0.05.
Abbreviations: NT= not treated (no drug); PA= phenylacetate; PB=
phenylbutyrate
Fig. 2 PDHC activity in tissues of mice treated with phenylacetate,
phenylbutyrate, DCA or combination of phenylbutyrate and DCA.
PDHC activity in brain, muscle, and liver mitochondrial fractions of
mice treated with saline (n=20), 250 mg/kg/day of phenylacetate (n=
5), 250 mg/kg/day of phenylbutyrate (n=10), 25 mg/kg/day of DCA
(n=5), 250 mg/kg/day of DCA (n=10), or with a combination of both
drugs each at the dose of 250 mg/kg/day (n=10). Averages±SD are
shown. a: p<0.05 compared to saline-treated mice; b: p<0.05 compared
to 250 mg/kg/day of DCA; c: p<0.05 compared to 250 mg/kg/day of
phenylbutyrate. Averages±SD are shown; * p<0.05. Abbreviations: PA=
phenylacetate; DCA= dichloroacetate; PB= phenylbutyrate
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docking simulation, we identified a putative binding site in the
N-terminal region of PDK3 (PDB 2Q8I) with a binding affin-
ity of −7.2 kcal/mol (Fig. 4c). This binding site consists of a
narrow hydrophobic channel formed by Leu27, Gln31,
Phe32, Phe35, Ser45, and Phe48 residues (Fig. 4d and
Supplementary Fig. 1b).
Combined treatment with phenylbutyrate and DCA
Because phenylbutyrate is predicted to bind to the ubiqui-
tously expressed PDK2 on a different site compared to
DCA (Fig. 4a and b), a known PDK inhibitor (Stacpoole
1989), we hypothesized that co-administration of both
drugs results in increased PDHC enzyme activity. To test
this hypothesis, we first incubated wild-type human fibro-
blasts with a combination of DCA and phenylbutyrate or
with DCA and phenylbutyrate alone as controls. A greater
increase in PDHC activity was detected in two indepen-
dent wild-type fibroblast cell lines incubated simultaneous-
ly with 1 mM or 10 mM of phenylbutyrate and DCA
compared to the sum of the effects of each drug alone
(Fig. 5, p<0.05). An increase of PDHC activity was also
Table 1 Kinetic data of the four PDKs




Ki (phenylbutyrate) mM Type of inhibition
PDK1 0.10±0.015 12.90±0.28 0.015±0.001 7.1±0.15 Uncompetitive
PDK2§ 0.20±0. 051 311.00±42 0.363±0.002 0.33±0.08§ Competitive
PDK3 0.31±0.028 16.86±0.38 0.019±0.0002 0.98±0.19 Uncompetitive
PDK4 0.23±0.021 19.79±0.39 0.023±0.063 N.D. –
The assay was performed in a final pH pf 7.4 and phenylbutyrate was added at the concentration of 0.25 mM, 0.5 mM, or 1 mM. The enzyme
concentrations of PDKs were 5.6-5.8 nM and PDK activity was measured as incorporation of [32 P]-phosphate into E1α with 0.2 mM [γ-32 P]ATP.
Ki for DCAwere previously found to be 1 mM for PDK1; 0.2 mM for PDK2; 8 mM for PDK3; and 0.5 mM for PDK4 (Bowker-Kinley et al 1998).
Km for ATP is not shown. Averages and standard errors of the mean are shown.
§ From competitive inhibition (Ferriero et al 2013); Abbreviations:
N.D. = not determined
Fig. 3 Differential inhibition of PDKs by phenylbutyrate. Lineweaver-
Burk plots of PDK1 (a), PDK3 (b), PDK4 (c) in the absence (■) or in the
presence of 0.25 mM (●), 0.5 mM (□), and 1 mM (○) of phenylbutyrate.
Averages and standard errors of the mean are shown. (d) Secondary plots
of the intercepts of lines from A and B against the relative inhibitor
concentrations to compare the inhibitory effect of phenylbutyrate on
different enzymes
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observed in fibroblasts from a patient with PDHC defi-
ciency harboring the p.N135S mutation in PDHA1 gene
(Ferriero et al 2013) (Fig. 6a, p<0.05). Consistent with
previous study (Ferriero et al 2013), this fibroblast cell
line responded to phenylbutyrate with a significant in-
crease of enzyme activity that was also increased by
DCA and was further enhanced by a combination of the
two drugs (Fig. 6a). Phenylbutyrate and DCA also resulted
in reduction of phosphorylated E1α and such reduction
was greater in cells incubated with a combination of the
two drugs (Fig. 6b and c). Wild-type mice administered
orally by gavage with a combination of 250 mg/kg/day
of DCA and 250 mg/kg/day of phenylbutyrate showed
higher PDHC enzyme activity in brain, muscle, and liv-
er mitochondrial fractions compared to mice adminis-
tered with each drug alone (Fig. 2, p<0.05). DCA ad-
ministered in mice at the dose of 25 mg/kg/day, that is
the dose administered in clinical trials in patients with
inherited PDHC deficiency (Stacpoole et al 2006), re-
sulted in no significant increase of PDHC activity in the
analyzed tissues (Fig. 2).
Fig. 4 Putative binding sites of phenylbutyrate on PDK2 (a, b) and
PDK3 (c, d). (a) Ribbon representation of human PDK2 structure (PDB
2BU8) and bound ligands represented in a space-filling model: ATP/
Mg2+ in gray; phenylbutyrate in green; DCA in red. ATP and DCA
are present in the X-ray structure while the phenylbutyrate position
was suggested by docking analysis. (b) Specific interactions of
phenylbutyrate (red, green, and white) with amino acid residues (stick
representation) at the binding sites of PDK2. (c) Ribbon representation of
human PDK3 structure (PDB 2Q8I) and bound ligands represented in a
space-filling model: ATP/Mg2+ in gray; phenylbutyrate in green. ATP is
present in the X-ray structure while phenylbutyrate binding site was sug-
gested by the docking analysis. (d) Specific interactions of
phenylbutyrate with amino acid residues (stick representation) of
PDK3 at the binding sites. Van der Waals interaction spheres of the
amino acid residues (stick representation) in contact with the inhibitor
have been removed for clarity in b and d. Supplementary Fig. 1 shows
Van der Waals interaction spheres of the amino acid residues in contact
with the inhibitor
Fig. 5 PDHC activity in wild-type fibroblasts incubated with
phenylbutyrate, DCA, or a combination of phenylbutyrate and DCA.
PDHC activity expressed as nmol/min/mg protein of mitochondrial
fractions of two wild-type cell lines (BA1020 and NA489) incubated
with 1 mM or 10 mM DCA, 1 mM or 10 mM of phenylbutyrate,
with the simultaneous presence of 1 mM DCA and 1 mM
phenylbutyrate, or with the simultaneous presence of 10 mM DCA
and 10mMphenylbutyrate. Averages±SD are shown. a: p<0.05 compared
to N.T.; b: p<0.05 compared to DCA 1 mM; c: p<0.05 compared to
phenylbutyrate 1 mM; d: p<0.05 compared to DCA 10 mM; e: p<0.05
compared to phenylbutyrate 10 mM. Abbreviations: NT= not treated (no
drug); DCA= dichloroacetate; PB= phenylbutyrate
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Discussion
PDK isoforms are up-regulated in cancer, diabetes, obesity,
and heart failure and are potential therapeutic targets for these
diseases (Roche and Hiromasa 2007). Moreover, PDK inhibi-
tion results in increased PDHC activity that has potential for
treatment of patients with inherited PDHC deficiency for
which no proven effective treatments are currently available
(Stacpoole et al 1997). In this study, we show that
phenylbutyrate and not its bioproduct phenylacetate is effec-
tive at increasing PDHC activity. These results are consistent
with a previous study showing that phenylbutyrate and not
phenylacetate binds BDK with high affinity and strongly in-
terferes with its enzymatic activity (Tso et al 2013). In vivo
phenylbutyrate is rapidly converted into phenylacetate. In
humans, following oral administration, phenylbutyrate con-
centration reaches a peak in the serum at 1.5 hours and be-
comes undetectable within about 6 hours (Yu et al 2001).
Therefore, as for urea cycle disorders, multiple daily adminis-
trations will likely be required to achieve sustained increase of
residual PDHC activity in vivo.
We investigated the inhibitory activity of phenylbutyrate
toward PDKs that negatively regulate PDHC by reversible
phosphorylation. Enzyme assay was performed using purified
Fig. 6 PDHC activity and phosphorylation of PDHC deficient cells
incubated with phenylbutyrate, DCA, or a combination of
phenylbutyrate and DCA. (a) PDHC activity expressed as nmol/min/mg
protein in a PDHC deficient patient harboring the mutation p.N135S in
the PDHA1 gene incubated with 1 mM or 10mMDCA, 1 mM or 10mM
of phenylbutyrate, with the simultaneous presence of 1 mM DCA and
1 mM phenylbutyrate, or with the simultaneous presence of 10mMDCA
and 10 mM phenylbutyrate. Averages±SD are shown. a: p<0.05
compared to N.T.; b: p<0.05 compared to DCA 1 mM; c: p<0.05
compared to phenylbutyrate 1 mM; d: p<0.05 compared to DCA
10 mM; e: p<0.05 compared to phenylbutyrate 10 mM. (b) Western
blotting for phosphorylated E1α and for total E1α protein in cells
incubated with the conditions reported in panel a. The images are
representative of two independent experiments. (c) Relative band
intensities of phosphorylated E1α normalized for total E1α from
two independent experiments. Averages±SD are shown. Abbreviations:
DCA= dichloroacetate; PB= phenylbutyrate; NT= not treated
(no drug)
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E1α and thus, we cannot rule out that results of kinetic studies
with PDKs may be different if the whole E1 heterotetramer is
used as a substrate. Nevertheless, PDK isoforms 1-to-3 were
found to be inhibited by phenylbutyrate. PDK2 and PDK3
were more strongly inhibited compared to PDK1 (Table 1)
and PDK2, that has the highest Vmax and lowest Ki
(Table 1), is likely to be the main target for phenylbutyrate
in vivo. In contrast, PDK4 that was previously proposed
as a lipid-responsive PDK isoform (Sugden and Holness
2003) was not inhibited. Therefore, in addition to BDK,
we identified PDK1-to-3 as additional molecular targets of
phenylbutyrate (Brunetti-Pierri et al 2011; Tso et al 2013).
Structural differences among the PDKs might explain the
different inhibitory effect of phenylbutyrate toward PDK2 and
the other isoenzymes. The binding site in PDK2 is predicted to
be located far from the E1α substrate binding site and the
competitive inhibition might be explained by conformational
changes induced by phenylbutyrate on PDK2 that reduce only
its affinity toward the E1α without affecting the kcat. The
binding affinity of PDK3 for E1α is strongly affected by bind-
ing to L2 domain of E2 and in the absence of such binding
PDK3 is less active (Baker et al 2000; Korotchkina and Patel
2001b). Uncompetitive inhibition is observed when the inhib-
itor binds the enzyme-substrate complex in a site that is dif-
ferent from the active site but induces a conformational
change that affects affinity and activity of the enzyme for the
substrate (Dixon and Webb 1979). We hypothesize that bind-
ing of phenylbutyrate to its putative site identified by docking
on PDK3 interferes with E1α binding through conformational
changes that negatively affect the catalytic activity. This hy-
pothesis can support the uncompetitive inhibition that is ex-
pected to be stronger in the presence of E2, which was absent
in our assay. The pocket involved in phenylbutyrate binding is
only present in PDK3 and is part of a region involved in
binding to the L2 domain of E2 subunit (Kato et al 2005).
Additional studies, such as X-ray crystallography of PDK-
phenylbutyrate complex, are required to confirm binding of
phenylbutyrate to the site predicted by the docking studies.
To explain the lack of inhibition of phenylbutyrate toward
PDK4, we compared the available structures of PDK2 and
PDK4 in their ADP-bound form. The PDK2-ADP bound
form (PDB 2BU8) results in a closed conformation with dis-
ordered C-term tails. In this form, the ATP lid is structured and
the protein has a high affinity for ATP. In contrast, the PDK4-
ADP bound form (PDB 2ZKJ) has an intermediate open con-
formation in which the ATP lid is unstructured and cross tails
are partially ordered (Wynn et al 2008). This form has lower
affinity for ATP and the ordered cross tails may impair en-
trance of phenylbutyrate in the structure. Different or even
opposite effects on PDKs have also been found with Nov3r
ligand (Knoechel et al 2006). Although binding to L2 domains
of E2 subunits on both PDK2 and PDK4, Nov3r inhibits
PDK2 but also stimulates PDK4 activity. The non-
conservative change in Leu32 of PDK4, that affects affinity
of the ligand for L2 domain, might explain the different effects
occurring upon binding of Nov3r (Knoechel et al 2006).
PDHC is a key enzyme in metabolism and plays an impor-
tant role in cancer. Through PDHC inhibition, PDK1 and
PDK3 are involved in hypoxia-inducedmetabolic switch from
aerobic respiration to aerobic glycolysis (i.e., the Warburg
effect) thus promoting cell survival (Kim et al 2006; Lu et al
2008; Kluza et al 2012; Ferriero and Brunetti-Pierri 2013).
Inhibition of PDK1 or PDK3 impairs cell growth and in-
creases oxygen consumption in human cancer cell lines
(Kim et al 2006; Lu et al 2008; McFate et al 2008).
Moreover, PDK1 depletion is effective in eradicating
cancer by activation of oncogene-induced senescence
(Kaplon et al 2013). Therefore, PDK1 and PDK3 inhi-
bition by phenylbutyrate might be therapeutically effec-
tive in cancer. Phenylbutyrate has indeed shown efficacy in
different cancers (Iannitti and Palmieri 2011). Similarly, DCA
has also shown efficacy in several different types of human
cancers (Michelakis et al 2008, 2010).
Recently, a mutation conferring PDK3 hyperactivity has
been reported as a cause of Charcot-Marie-Tooth disease
(Kennerson et al 2013) and by inhibition of PDK3 activity,
phenylbutyrate may prevent PDHC hyper-phosphorylation
that has been recognized as the underlying cause of peripheral
neuropathy. In addition, phenylbutyrate might be effective for
therapy of patients with inherited PDHC deficiency, an inborn
error of metabolism that severely affects the central nervous
system (Brown et al 1994; DeBrosse et al 2012).
In this study, we have shown that a combination of
phenylbutyrate and DCA results in greater increase of
PDHC activity compared to each drug alone. DCA has been
proposed as a treatment for patients with inborn errors of
mitochondrial metabolism (Coude et al 1978) and its efficacy
has been investigated in clinical trials. A randomized con-
trolled trial of DCA at the dose of 25 mg/kg/day in children
with PDHC deficiency or defects in respiratory chain
enzymes showed good tolerance and sustained reduc-
tions of venous blood and cerebrospinal fluid lactate
concentrations (Stacpoole et al 2006). However, some con-
cerns were raised because of worsening of lower extremity
nerve conduction in some patients (Stacpoole et al 2008),
particularly in adults (Kaufmann et al 2006).
In mice, DCA and phenylbutyrate both increased PDHC
activity in brain, muscle, and liver at the dose of 250 mg/kg/
day whereas no increase of enzyme activity was detected with
25 mg/kg/day of DCA that corresponds to the dose adminis-
tered to patients with cancer (Dunbar et al 2014) and PDHC
deficiency (Stacpoole et al 2006). It is unknown whether
higher dose of DCA are needed to obtain clinically relevant
outcomes and whether such higher doses are tolerated in
humans. Nevertheless, DCA is metabolized in humans at a
lower rate compared to mice and high doses might not be
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required (Stacpoole et al 1998). Phenylbutyrate instead was
effective in mice at increasing PDHC enzyme activity at the
dose of 250 mg/kg/day that is safely administered to patients
with urea cycle disorders (Haberle et al 2012). The results of
our study show that combination of phenylbutyrate and DCA
has the potential of resulting in greater efficacy compared to
the single drug treatments. However, careful evaluation of
toxicity deriving from this drug combination would be re-
quired prior to testing in patients.
In conclusion, the greater increase of PDHC activity both
in cells and in vivo suggests that combined therapy with drugs
binding to different PDK sites, such as phenylbutyrate and
DCA, has potential to enhance therapeutic efficacy by greater
enhancement of enzyme activity. Such combined therapy
could be applied for therapy of patients with cancer, PDHC
deficiency, and several other disorders that can benefit from
PDK inhibition.
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